Trial Information
Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function
Inclusion Criteria:
1. Subjects with Idiopathic Parkinson's Disease
2. Subjects who are willing and able to participate in the trial and has provided
written, informed consent.
Exclusion Criteria:
1. Subjects who are allergic to Whey protein (HMS 90®).
2. Subjects who are treated with chemotherapy .
3. Subjects with any history of neurodegenerative diseases, e.g., Alzheimer's disease.
4. Subjects with history of diabetes. 4.5. Subjects with abnormal liver function test
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care
Outcome Measure:
Biomarkers of oxidative stress, i.e., plasma glutathione (reduced and oxidized forms), urinary 8-hydroxydeoxyguanosine, and urinary total antioxidant status
Outcome Time Frame:
6 months
Safety Issue:
Yes
Principal Investigator
Roongroj Bhidayasiri, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Chulalongkorn University
Authority:
Thailand: Ethical Committee
Study ID:
53653
NCT ID:
NCT01662414
Start Date:
April 2011
Completion Date:
December 2012
Related Keywords:
- Parkinson Disease
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Basal Ganglia Diseases
- Brain Diseases
- Central Nervous System Diseases
- Ganglion Cysts
- Movement Disorders
- Nervous System Diseases
- Parkinson Disease
- Parkinsonian Disorders
- Neurodegenerative Diseases